肠安康新组方抗溃疡性结肠炎大鼠的机制研究

目的研究肠安康新组方抗溃疡性结肠炎(UC)大鼠可能的作用机制。方法制备三硝基苯磺酸(TNBS)/乙醇诱导溃疡性结肠炎(UC)大鼠模型,动物随机分为9组:正常对照组、模型对照组、柳氮磺胺吡啶(SASP)组、肠安康新组方口服给药组(1.12、0.56、0.28 g.kg-1)、肠安康新组方结肠定位给药组(1.12、0.56、0.28 g.kg-1)。造模后24 h开始给药,每天1次,连续给药7 d,从造模开始至实验结束共9d。实验结束后紫外分光光度法测诱导型一氧化氮合酶(iN-OS)活性、一氧化氮(NO)含量,ELISA法测白介素-8(IL-8)含量,免疫组化法检测c-Jun表达。结果与模型组相比,肠安康新组方各给药组均可改善升高的iNOS、NO、IL-8、c-Jun。结论肠安康新组方抗UC作用可能与抑制炎症因iN-OS、NO、IL-8的产生和c-Jun的激活有关。

Mechanisms of new Chang-an-kang on ulcerative colitis in rat

Aim To observe inducible nitric oxide synthase(iNOS) activity,nitricoxide(NO) levels,interleukin-8(IL-8)levels,and c-Jun expression in colonic tissue to evaluate the possible mechanism of oral administration and colon-specific drug delivery of new Chang-an-kang.Methods Trinitrobenzene sulfonic acid(TNBS)/ethanol-induced ulcerative colitis(UC) rat model was prepared,and the model rats were randomly divided into eight groups:model control group,sulfasalazine tablets(SASP) group,1.12,0.56,0.28 g·kg-1 oral administration group and 1.12,0.56,0.28 g·kg-1 colon-specific drug delivery group.Rats were given drugs after 24h of modeling for 7 days successively,and on the 9th day,iNOS activity,NO levels,IL-8 levels,and c-Jun expression were detected.Results There was a significant increase in iNOS activity,NO levels,IL-8 levels,and c-Jun expression between normal group and model group.Oral administration and colon-specific drug delivery of new Chang-an-kang decreased iNOS activity,NO levels,IL-8 levels,and c-Jun expression,and colon-specific drug delivery were better than oral administration.Conclusions Oral administration and colon-specific drug delivery of new Chang-an-kang may play their therapeutic role through inhibiting the inflammation due to iNOS,NO,IL-8 generation and c-Jun activation.